Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $215.00

Becton, Dickinson and Company (NYSE:BDX) had its price objective increased by Stifel Nicolaus from $210.00 to $215.00 in a research note issued to investors on Wednesday morning, MarketBeat Ratings reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

BDX has been the topic of several other reports. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Argus boosted their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Piper Sandler dropped their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday, November 7th. Bank of America raised their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $207.64.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock opened at $202.78 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The company has a market capitalization of $57.77 billion, a PE ratio of 34.78, a P/E/G ratio of 2.27 and a beta of 0.23. The company has a 50 day moving average price of $193.11 and a 200-day moving average price of $188.12. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.1%. The ex-dividend date was Monday, December 8th. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael David Garrison sold 629 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $196.03, for a total value of $123,302.87. Following the completion of the sale, the executive vice president owned 13,105 shares in the company, valued at approximately $2,568,973.15. This represents a 4.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 1,052 shares of company stock worth $201,235 over the last three months. Corporate insiders own 0.40% of the company’s stock.

Institutional Trading of Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Bill Few Associates Inc. boosted its holdings in Becton, Dickinson and Company by 0.7% in the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock valued at $1,362,000 after purchasing an additional 55 shares during the last quarter. Gilbert & Cook Inc. lifted its holdings in shares of Becton, Dickinson and Company by 2.0% in the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after buying an additional 56 shares during the period. Mendel Money Management boosted its stake in shares of Becton, Dickinson and Company by 2.6% in the second quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after buying an additional 58 shares during the last quarter. Focus Financial Network Inc. boosted its stake in shares of Becton, Dickinson and Company by 2.2% in the third quarter. Focus Financial Network Inc. now owns 2,692 shares of the medical instruments supplier’s stock worth $504,000 after buying an additional 58 shares during the last quarter. Finally, Phillips Wealth Planners LLC grew its holdings in Becton, Dickinson and Company by 2.7% during the third quarter. Phillips Wealth Planners LLC now owns 2,241 shares of the medical instruments supplier’s stock worth $430,000 after acquiring an additional 58 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.